Crescentic glomerulonephritis in a patient with advanced lung cancer during erlotinib therapy
نویسندگان
چکیده
1. Kim S, Oh J, Chung W et al. Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study. Nephrol Dial Transplant 2009; 24: 2899–2908 2. Hoff CM. In vitro biocompatibility performance of physioneal. Kidney Int Suppl 2003; S57–S74 3. Pajek J, Kveder R, Bren A et al. Short-term effects of bicarbonate/ lactate-buffered and conventional lactate-buffered dialysis solutions on peritoneal ultrafiltration: a comparative crossover study. Nephrol Dial Transplant 2009; 24: 1617–1625 4. Glik A, Douvdevani A. T lymphocytes: the ‘cellular’ arm of acquired immunity in the peritoneum. Perit Dial Int 2006; 26: 438–448 5. Saeed AI, Sharov V, White J et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 2003; 34: 374–378
منابع مشابه
Duodenal Perforation Secondary to Erlotinib Therapy in a Patient With Non-Small Cell Lung Cancer.
Lung cancer is a lethal disease with high mortality, and treatment modality varies with type of tumor and stage of the disease. Targeted molecular therapies have been developed for patients with advanced non-small cell lung cancer. The presence of epidermal growth factor receptor (EGFR) mutation qualifies the patient for EGFR-TKI (tyrosine kinase inhibitor) therapy such as erlotinib, which is n...
متن کاملHigh-dose corticosteroid therapy for erlotinib-induced interstitial lung disease in Japanese patient with advanced pancreatic cancer.
CONTEXT Erlotinib is a selective epidermal growth factor receptor tyrosine kinase inhibitor used as a target therapy against non-small lung cancer and advanced pancreatic cancer. A regimen of erlotinib plus gemcitabine has been proven to prolong overall survival in the patient with advanced pancreatic cancer. In addition to common adverse effects, such as diarrhea, mucositis and skin rash (acne...
متن کاملApatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case report
Lung adenocarcinoma is the most common pathological pattern of lung cancer. During the past decades, a number of targeted agents have been explored to treat advanced lung adenocarcinoma. In the present clinical practice, antagonists of the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF)-directed therapies are widely used. In the former category, the agent e...
متن کاملOverview of advanced non-small-cell lung cancer treatment in Mexico
BACKGROUND Lung cancer is the leading cause of cancer-related deaths among males and the second among females. The importance of lung cancer is a major public health problem and there is a need to find effective therapies for its management. Erlotinib has been approved to treat non-small-cell lung cancer. The author's experience in the use of erlonitib in lung cancer patients in Mexico City is ...
متن کاملErlotinib-induced complete response in a patient with epidermal growth factor receptor wild-type lung adenocarcinoma after chemotherapy failure: a case report
INTRODUCTION The efficacy of erlotinib in advanced non-small-cell lung cancer has been demonstrated in several trials, but only two cases of complete and prolonged response in wild-type epidermal growth factor receptor locally advanced lung cancer have been published. CASE PRESENTATION We discuss a case of a 67-year-old Caucasian man, a former heavy cigarette smoker, with a diagnosis of wild-...
متن کامل